Kronos Bio LLC (KRON) Stock Price
Kronos Bio LLC Price
Revenue has compounded at 78.7% per year over the past 2 years to 9.85 M USD. Kronos Bio LLC's net margin stands at -874.1%, up from -4,192.4% several years earlier. Analysts set a median price target of 2.30 USD, implying 160.8% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Kronos Bio LLC stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Kronos Bio LLC business model & stock analysis
Frequently asked questions about Kronos Bio LLC
The business model of Kronos Bio Inc. focuses on developing and commercializing novel therapies for the treatment of cancer and other serious diseases. By leveraging its proprietary platform, the company aims to identify and target specific vulnerabilities in cancer cells, resulting in more effective and personalized therapies. Kronos Bio Inc. employs a multi-disciplinary approach, combining expertise in chemistry, structural biology, and genomics to accelerate the discovery and development of potential drug candidates. With a strong commitment to improving patient outcomes, Kronos Bio Inc. is devoted to advancing its pipeline of innovative medicines to address unmet medical needs in oncology and beyond.
Kronos Bio Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Kronos Bio Inc in the market are other biotechnology companies operating in the same therapeutic areas. Some prominent competitors include XYZ Biotech, ABC Biopharma, and LMN Therapeutics. However, Kronos Bio distinguishes itself through its innovative drug discovery platform and its focus on personalized medicine. With its cutting-edge technology and strong pipeline, Kronos Bio Inc stands out amidst competition and aims to revolutionize the field of biotechnology.
Kronos Bio Inc is a biopharmaceutical company that focuses on developing novel therapies for cancer and other serious diseases. Established in 2017, the company is based in San Mateo, California. Kronos Bio Inc utilizes its proprietary discovery platform to identify and target dysregulated transcription factors, which play a crucial role in disease progression. By developing small molecule modulators, they aim to disrupt disease-driving transcriptional programs. With a focus on precision medicine, Kronos Bio Inc aims to provide effective and personalized treatment options for patients. They have partnered with leading academic institutions and have a diverse pipeline of potential therapeutics.
Kronos Bio Inc, a leading biopharmaceutical company, has achieved remarkable milestones to date. The company has successfully developed and advanced several innovative therapeutic programs. Notably, Kronos Bio Inc received the prestigious Breakthrough Therapy Designation by the U.S. FDA for its novel drug candidate, entospletinib. This designation recognizes the remarkable potential of entospletinib in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Kronos Bio Inc has also formed strategic partnerships with renowned organizations to expedite the development and commercialization of its pipeline. These milestones reflect the commitment and groundbreaking research efforts of Kronos Bio Inc, positioning the company as a frontrunner in the biopharmaceutical industry.
Kronos Bio Inc is primarily present in the United States.
Kronos Bio Inc represents a strong set of values and a clear corporate philosophy. The company prioritizes innovation and scientific excellence in its efforts to develop transformative therapies for cancer patients. Kronos Bio Inc firmly believes in collaboration and maintains partnerships with leading academic institutions and industry leaders to accelerate their research and development. With a focus on precision medicine, the company aims to uncover and target molecular vulnerabilities to address unmet medical needs. By leveraging its expertise in targeted protein degradation, Kronos Bio Inc strives to make a significant impact in the field of oncology.
Analysts currently set an average price target of 2.30 USD for the Kronos Bio LLC stock (median: 2.30 USD), implying +160.8 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Kronos Bio LLC stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Kronos Bio LLC to generate revenue of 12.83 M USD and earnings per share of -1.36 USD.
Converted at the current exchange rate, the Kronos Bio LLC share trades at 0.79 EUR (0.88 USD).
The Kronos Bio LLC share (KRON) is listed on 1 stock exchanges, including: NASDAQ (KRON).
The company Kronos Bio Inc. is a biotechnology company that focuses on the development and production of novel therapeutics for cancer patients. The company is headquartered in Cambridge, USA and is one of the most promising start-ups in the pharmaceutical industry. Kronos Bio's business model is based on a wide range of research topics, including biomarker discovery, drug research, and preclinical and clinical study developments. Kronos Bio aims to explore new treatment options for cancer patients based on genetic and epigenetic mutations to advance personalized medicine. Kronos Bio's products focus on cancer treatments and consist of a pipeline of therapeutics in various stages of development. For example, the drug "KB-0742" is in preclinical development. This drug could interact with a specific mutation in a cancer-related gene to selectively destroy cancer cells. Another product of the company is "KB-0742", a potentially promising drug against myelodysplastic syndromes (MDS) and leukemia. It is currently in clinical development and initial results show potential efficacy against MDS. Kronos Bio aims to distribute its products in different markets worldwide and secure the intellectual property of its products through patents and licenses. To test and validate the efficacy of their products, Kronos Bio works closely with government organizations, universities, and private laboratories. Kronos Bio's research focus is based on the discovery of novel therapeutics through the combination of genetic and chemical approaches. Their research team consists of industry veterans, scientists, and data scientists who develop unique and tailored models to test and validate the effects of their products. In summary, Kronos Bio Inc. has a smart and ambitious business model. The company places special emphasis on the development of personalized medicine and explores innovative products and technologies to provide cancer patients with the best possible treatment approach. With its diverse pipeline and project development, Kronos Bio strives to bring unique therapeutics to the market to improve the lives of cancer patients worldwide.
The expected revenue of Kronos Bio LLC is 12.83 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Kronos Bio LLC is -82.31 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Kronos Bio LLC is currently -0.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Kronos Bio LLC stock.
The price-to-sales ratio (P/S) of Kronos Bio LLC is currently 4.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Kronos Bio LLC stock.
The Eulerpool Quality Score for Kronos Bio LLC is 2/10.
The ISIN of Kronos Bio LLC is US50107A1043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Kronos Bio LLC is A2QD64. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Kronos Bio LLC is KRON. The ticker symbol is used to trade Kronos Bio LLC shares on the stock exchange.
Kronos Bio LLC stock
Kronos Bio LLC Peer Group
Kronos Bio LLC Ticker
Kronos Bio LLC FIGI
All fundamentals and in-depth analysis of Kronos Bio LLC
Our stock analysis for Kronos Bio LLC stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kronos Bio LLC. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.